Alzheimer’s drugs may not work and could raise brain risks
A major review finds Alzheimer’s drugs that remove amyloid may do little good—and could carry hidden risks.
Date: May 4, 2026 Source: Cochrane Summary: Drugs designed to clear amyloid beta from the brain—once seen as a promising path to slowing Alzheimer’s—may not actually help patients in any meaningful way, according to a major review of over 20,000 participants. Even more concerning, they may increase the risk of brain swelling and bleeding, sometimes without obvious symptoms. Share: Facebook Twitter Pinterest LinkedIN Email FULL STORY
A major Cochrane review has found that drugs designed to target amyloid beta proteins in the brain are unlikely to provide meaningful benefits for patients. At the same time, these treatments appear to increase the risk of brain swelling and bleeding.
Amyloid beta is a protein that builds up in the brains of people with Alzheimer's disease, often years before symptoms appear. Scientists have long believed that removing these protein deposits could slow or prevent the disease. Based on this idea, several drugs have been developed to clear amyloid from the brain.
Large Review of Alzheimer's Drug Trials
The new analysis combined results from 17 clinical trials involving 20,342 participants. All of the studies focused on people with mild cognitive impairment or early-stage Alzheimer's dementia. Researchers have suggested that targeting amyloid early in the disease might offer the best chance of slowing progression.
Effects Fall Below Meaningful Clinical Thresholds
The findings showed that the impact of anti-amyloid drugs on memory decline and dementia severity was either nonexistent or extremely small. In fact, the measured effects were well below the level considered meaningful for patients in clinical practice.
"Unfortunately, the evidence suggests that these drugs make no meaningful difference to patients," says lead author Francesco Nonino, neurologist and epidemiologist at the IRCCS Institute of Neurological Sciences of Bologna, Italy. "There is now a convincing body of evidence converging on the conclusion that there is no clinically meaningful effect. While early trials showed results that were statistically significant, it is important to distinguish between this and clinical relevance. It is common for trials to find statistically significant results that do not translate into a meaningful clinical difference for patients."
Increased Risk of Brain Swelling and Bleeding
Beyond the lack of benefit, the review also identified safety concerns. Anti-amyloid drugs were linked to a higher likelihood of swelling and bleeding in the brain. In many cases, these changes were only visible on brain scans and did not cause obvious symptoms. However, the long-term consequences remain uncertain because reporting of symptoms varied across studies.
Rethinking the Future of Alzheimer's Treatment
Based on these results, the researchers conclude that continuing to focus on removing amyloid beta is unlikely to lead to major improvements for patients. Although the drugs do reduce amyloid levels in the brain, this does not appear to translate into better outcomes.
The authors suggest that future research should shift toward other biological pathways involved in Alzheimer's disease. Many studies are already exploring alternative approaches.
"I see Alzheimer's patients in my clinic every week and I wish I had an effective treatment to offer them," says senior author Edo Richard, Professor of Neurology at Radboud University Medical Centre. "Existing approved drugs offer some benefit for some patients, but there remains a high unmet need for more effective treatments. Sadly, anti-amyloid drugs do not offer this and bring additional risks. Given the absence of correlation between amyloid removal and clinical benefit, we need to explore other pathways to help address this devastating disease."
Story Source:
Materials provided by Cochrane. Note: Content may be edited for style and length.
Journal Reference:
- Francesco Nonino, Silvia Minozzi, Luisa Sambati, Cinzia Del Giovane, Elisa Baldin, Maria Chiara Bassi, Claudia De Santis, Marien Gonzalez-Lorenzo, Luca Vignatelli, Graziella Filippini, Edo Richard. Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. Cochrane Database of Systematic Reviews, 2026; 2026 (4) DOI: 10.1002/14651858.CD016297
Cite This Page:
Cochrane. "Alzheimer’s drugs may not work and could raise brain risks." ScienceDaily. ScienceDaily, 4 May 2026. <www.sciencedaily.com/releases/2026/05/260502233915.htm>. Cochrane. (2026, May 4). Alzheimer’s drugs may not work and could raise brain risks. ScienceDaily. Retrieved May 4, 2026 from www.sciencedaily.com/releases/2026/05/260502233915.htm Cochrane. "Alzheimer’s drugs may not work and could raise brain risks." ScienceDaily. www.sciencedaily.com/releases/2026/05/260502233915.htm (accessed May 4, 2026).Explore More
from ScienceDaily RELATED STORIES Hidden Alzheimer’s Warning Signs Found in Parkinson’s Patients Without Dementia Sep. 28, 2025 Researchers in Japan discovered that Parkinson’s patients diagnosed in their 80s are far more likely to show signs of amyloid buildup, a hallmark of Alzheimer’s, even without dementia symptoms. ... Is Long-Term Beta-Blocker Therapy Needed After a Heart Attack? Aug. 30, 2024 The appropriate duration of beta-blocker treatment after a heart attack (a myocardial infarction [MI]) is unknown in patients who do not need to take beta-blockers for another reason. In the ABYSS ... Maternal Inheritance of Alzheimer's Disease Tied to Increased Risk of Developing Disease June 17, 2024 Researchers analyzed 4,400 cognitively unimpaired adults with amyloid imaging, finding increased amyloid in those who reported that their mothers had symptoms of Alzheimer's disease (AD). ... Alzheimer‘s: Amyloid and Tau Are a Perilous Couple Mar. 30, 2022 In the course of Alzheimer's disease, two proteins called 'amyloid' and 'tau' accumulate in the brain. A new study with more than 200 participants now provides insights into ... Does Alzheimer’s Disease Start Inside Nerve Cells? Aug. 18, 2021 An experimental study has revealed that the Alzheimer's protein amyloid-beta accumulates inside nerve cells, and that the misfolded protein may then spread from cell to cell via nerve fibers. ... Signaling Molecule May Help Prevent Alzheimer's Disease July 14, 2021 The main driver of Alzheimer's disease is excessive inflammation in the brain that is triggered by cells called astrocytes and microglia in response to high levels of amyloid beta deposits and ... TRENDING AT SCITECHDAILY.comMillions of People Have Osteopenia Without Realizing It – Here’s What You Need To Know
AI Detects “Invisible” Signs of Pancreatic Cancer Years Before Diagnosis
World-First Study Reveals Human Hearts Can Regenerate After a Heart Attack
Why Your Dreams Feel So Real Sometimes and So Strange Other Times
Схожі новини
Who is Charles Lieber? Convicted Harvard scientist now leading China’s research to link the brain with computers
Вінницька психоневрологічна лікарня отримала автомобіль для перевезення маломобільних пацієнтів
У мережі показали відео удару по Мерефі, який вбив 5 людей
